ECSP21015491A - Administración prolongada de lasmiditan por la noche para la prevención de la migraña - Google Patents
Administración prolongada de lasmiditan por la noche para la prevención de la migrañaInfo
- Publication number
- ECSP21015491A ECSP21015491A ECSENADI202115491A ECDI202115491A ECSP21015491A EC SP21015491 A ECSP21015491 A EC SP21015491A EC SENADI202115491 A ECSENADI202115491 A EC SENADI202115491A EC DI202115491 A ECDI202115491 A EC DI202115491A EC SP21015491 A ECSP21015491 A EC SP21015491A
- Authority
- EC
- Ecuador
- Prior art keywords
- migraine
- prevention
- night
- meditan
- prolonged administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere al uso prolongado de lasmiditan por la noche para la prevención de la migraña, particularmente la migraña resistente al tratamiento que se define en el presente documento como migraña refractaria a dos o más esquemas de prevención o tratamiento previos de monoterapia y/o terapia doble.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726585P | 2018-09-04 | 2018-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21015491A true ECSP21015491A (es) | 2021-04-29 |
Family
ID=68051892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202115491A ECSP21015491A (es) | 2018-09-04 | 2021-03-04 | Administración prolongada de lasmiditan por la noche para la prevención de la migraña |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20210338655A1 (es) |
| EP (2) | EP3846810B1 (es) |
| JP (2) | JP7321256B2 (es) |
| KR (1) | KR102649644B1 (es) |
| CN (1) | CN112638383A (es) |
| AU (2) | AU2019336667B2 (es) |
| BR (1) | BR112021002945A2 (es) |
| CA (1) | CA3111205A1 (es) |
| CL (1) | CL2021000529A1 (es) |
| CO (1) | CO2021002766A2 (es) |
| CR (1) | CR20210126A (es) |
| DK (1) | DK3846810T3 (es) |
| DO (1) | DOP2021000039A (es) |
| EA (1) | EA202190440A1 (es) |
| EC (1) | ECSP21015491A (es) |
| ES (1) | ES2967665T3 (es) |
| FI (1) | FI3846810T3 (es) |
| HR (1) | HRP20231587T1 (es) |
| HU (1) | HUE064519T2 (es) |
| IL (1) | IL281208A (es) |
| JO (1) | JOP20210033A1 (es) |
| LT (1) | LT3846810T (es) |
| MA (1) | MA53551B1 (es) |
| MD (1) | MD3846810T2 (es) |
| MX (1) | MX2021002474A (es) |
| NZ (1) | NZ774400A (es) |
| PE (1) | PE20211599A1 (es) |
| PH (1) | PH12021550448A1 (es) |
| PL (1) | PL3846810T3 (es) |
| PT (1) | PT3846810T (es) |
| RS (1) | RS64857B1 (es) |
| SG (1) | SG11202101530PA (es) |
| SI (1) | SI3846810T1 (es) |
| TW (1) | TWI826514B (es) |
| WO (1) | WO2020051137A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2937315A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| BR112023001615A2 (pt) * | 2020-07-29 | 2023-04-04 | Allergan Pharmaceuticals Int Ltd | Tratamento para enxaqueca |
| US11717515B2 (en) | 2020-12-22 | 2023-08-08 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
| TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| NZ596161A (en) * | 2009-04-02 | 2013-11-29 | Colucid Pharmaceuticals Inc | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide |
| US8697876B2 (en) * | 2010-04-02 | 2014-04-15 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists |
-
2019
- 2019-09-02 TW TW108131567A patent/TWI826514B/zh active
- 2019-09-03 CA CA3111205A patent/CA3111205A1/en active Pending
- 2019-09-03 JO JOP/2021/0033A patent/JOP20210033A1/ar unknown
- 2019-09-03 US US17/271,950 patent/US20210338655A1/en active Pending
- 2019-09-03 ES ES19773583T patent/ES2967665T3/es active Active
- 2019-09-03 SG SG11202101530PA patent/SG11202101530PA/en unknown
- 2019-09-03 EA EA202190440A patent/EA202190440A1/ru unknown
- 2019-09-03 MA MA53551A patent/MA53551B1/fr unknown
- 2019-09-03 EP EP19773583.0A patent/EP3846810B1/en active Active
- 2019-09-03 HU HUE19773583A patent/HUE064519T2/hu unknown
- 2019-09-03 FI FIEP19773583.0T patent/FI3846810T3/fi active
- 2019-09-03 LT LTEPPCT/US2019/049340T patent/LT3846810T/lt unknown
- 2019-09-03 RS RS20231107A patent/RS64857B1/sr unknown
- 2019-09-03 NZ NZ774400A patent/NZ774400A/en unknown
- 2019-09-03 MX MX2021002474A patent/MX2021002474A/es unknown
- 2019-09-03 JP JP2021512380A patent/JP7321256B2/ja active Active
- 2019-09-03 WO PCT/US2019/049340 patent/WO2020051137A1/en active Application Filing
- 2019-09-03 MD MDE20210640T patent/MD3846810T2/ro unknown
- 2019-09-03 EP EP23195738.2A patent/EP4279132A3/en active Pending
- 2019-09-03 BR BR112021002945-1A patent/BR112021002945A2/pt unknown
- 2019-09-03 KR KR1020217005977A patent/KR102649644B1/ko active IP Right Grant
- 2019-09-03 CR CR20210126A patent/CR20210126A/es unknown
- 2019-09-03 SI SI201930647T patent/SI3846810T1/sl unknown
- 2019-09-03 HR HRP20231587TT patent/HRP20231587T1/hr unknown
- 2019-09-03 PT PT197735830T patent/PT3846810T/pt unknown
- 2019-09-03 DK DK19773583.0T patent/DK3846810T3/da active
- 2019-09-03 PE PE2021000286A patent/PE20211599A1/es unknown
- 2019-09-03 AU AU2019336667A patent/AU2019336667B2/en active Active
- 2019-09-03 CN CN201980055464.3A patent/CN112638383A/zh active Pending
- 2019-09-03 PL PL19773583.0T patent/PL3846810T3/pl unknown
-
2021
- 2021-03-01 CO CONC2021/0002766A patent/CO2021002766A2/es unknown
- 2021-03-02 PH PH12021550448A patent/PH12021550448A1/en unknown
- 2021-03-02 DO DO2021000039A patent/DOP2021000039A/es unknown
- 2021-03-02 IL IL281208A patent/IL281208A/en unknown
- 2021-03-03 CL CL2021000529A patent/CL2021000529A1/es unknown
- 2021-03-04 EC ECSENADI202115491A patent/ECSP21015491A/es unknown
-
2022
- 2022-12-22 AU AU2022291568A patent/AU2022291568A1/en active Pending
-
2023
- 2023-07-25 JP JP2023120471A patent/JP2023156344A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| CL2018003588A1 (es) | Uso de inhibidores de miostatina y terapias de combinación. | |
| CL2019001292A1 (es) | Nuevos derivados de quinolina. | |
| ECSP21015491A (es) | Administración prolongada de lasmiditan por la noche para la prevención de la migraña | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| CL2020000301A1 (es) | Nuevos derivados de quinolina. | |
| DOP2017000268A (es) | Metodos y kits para tratar depresion | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112017002332A2 (pt) | terapia de combinação para o tratamento de um paramixovírus | |
| BR112016029041A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| NI201400104A (es) | Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento | |
| CR20180495A (es) | Deribados de indol sustituidos como inhibidores de replicación viral del dengue | |
| CR20180493A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| BR112017006299A2 (pt) | derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue | |
| CR20190447A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| CL2019003078A1 (es) | Nuevos derivados de pirazol bicíclicos. | |
| CL2019001996A1 (es) | Usos terapéuticos de un polvo de insectos. | |
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CO2021000210A2 (es) | Apirasas solubilizadas, métodos y usos | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| CL2016001977A1 (es) | Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias. |